Broadwood Partners, L.P. Buys 23,000 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the business's stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average cost of $24.33 per share, for a total transaction of $559,590.00. Following the purchase, the insider now directly owns 10,848,631 shares of the company's stock, valued at $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The stock was purchased at an average price of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Stock Performance

NASDAQ:STAA traded down $1.18 during trading hours on Wednesday, hitting $24.26. The stock had a trading volume of 556,037 shares, compared to its average volume of 702,254. The business's 50 day moving average is $28.43 and its 200-day moving average is $34.63. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 55.14 and a beta of 0.59. STAAR Surgical has a one year low of $23.72 and a one year high of $52.68.

Analysts Set New Price Targets

STAA has been the topic of several recent research reports. Stifel Nicolaus reduced their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a research note on Monday, August 26th. Stephens raised shares of STAAR Surgical to a "hold" rating in a research note on Monday, December 2nd. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, October 31st. Finally, Canaccord Genuity Group cut their price target on STAAR Surgical from $31.00 to $28.00 and set a "hold" rating on the stock in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $42.83.

Hedge Funds Weigh In On STAAR Surgical

Several institutional investors and hedge funds have recently made changes to their positions in STAA. Mutual of America Capital Management LLC lifted its holdings in STAAR Surgical by 214.7% during the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier's stock worth $1,260,000 after acquiring an additional 18,051 shares in the last quarter. ClariVest Asset Management LLC acquired a new stake in shares of STAAR Surgical during the second quarter worth about $1,223,000. Algert Global LLC lifted its holdings in shares of STAAR Surgical by 13.5% during the 2nd quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier's stock valued at $5,554,000 after purchasing an additional 13,901 shares in the last quarter. Granite Investment Partners LLC acquired a new position in shares of STAAR Surgical in the 2nd quarter valued at approximately $17,237,000. Finally, Polar Asset Management Partners Inc. increased its stake in STAAR Surgical by 44.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier's stock worth $6,271,000 after purchasing an additional 51,800 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.